Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates, including several with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infections disease - HIV, hepatitis and resistant bacterial infections. Our drug candidates tend to be small molecules directed at the $40 billion worldwide infectious disease market. Achillion's lead product candidate is elvucitabine for use in patients chronically infected with HIV, which has demonstrated potent anti-HIV activity, as well as an exceptionally long half-life, a feature that may stem the emergence of drug resistance.
Achillion's powerful drug discovery engine embodies both a conventional medicinal chemistry approach directed at classical anti-infective molecular targets and its novel chemistry approach directed at classical anit-infective molecular targets and its novel Zinc Finger Targeting (ZFT) drug discovery technology focusing on novel proteins containing zinc finger motifs. ZFT has broad applicability against a variety of organisms an cell types: viruses, fungi, parasites, bacteria and cancer. Using ZFT technology, Achillion selectively targets diverse pathogens to apply its medicinal chemistry and drug development expertise to develop breakthrough products to treat serious infectious diseases with unmet medical needs.
CT Employees: 40
World Employees: 40